Ms. Patricia Powers-Feigel, Director Operations, on behalf of Midas Pharmaceuticals, Inc., 300 Interpace Parkway, Suite 420, Parsippany, NJ, 07054-1100, filed on February 24, 2015.; The Petition seeks a formal opinion from the Department as to ...  

  •  

    DEPARTMENT OF BUSINESS AND PROFESSIONAL REGULATION

    Drugs, Devices and Cosmetics

    NOTICE IS HEREBY GIVEN that Division of Drugs, Devices and Cosmetics has received the petition for declaratory statement from Ms. Patricia Powers-Feigel, Director Operations, on behalf of Midas Pharmaceuticals, Inc., 300 Interpace Parkway, Suite 420, Parsippany, NJ, 07054-1100, filed on February 24, 2015. The petition seeks the agencys opinion as to the applicability of Chapter 499, F.S. as it applies to the petitioner.

    The Petition seeks a formal opinion from the Department as to whether the Petitioner is required to be licensed by the State of Florida, under Chapter 499, F.S., to distribute limited quantities of Active Pharmaceutical Ingredients to licensed prescription drug manufacturers in Florida for use in research and development purposes in support of an Abbreviated New Drug Application and not for commercial sale.

    A copy of the Petition for Declaratory Statement may be obtained by contacting: The Division of Drugs, Devices and Cosmetics, 1940 N. Monroe Street, Suite 26A, Tallahassee, FL 32399-1047.

    Please refer all comments to: Reggie Dixon, Division Director, Division of Drugs, Devices and Cosmetics, 1940 N. Monroe Street, Suite 26A, Tallahassee, FL 32399-1047, website: http://interredesignalpha/dbpr/ddc/ddc_division_notices.html.

Document Information

Meeting:
Chapter 499, F.S.
Contact:
The Division of Drugs, Devices and Cosmetics, 1940 N. Monroe Street, Suite 26A, Tallahassee, FL 32399-1047.